Open AccessQuality of Life and Targeted Treatment for Metastatic Renal Cell Carcinoma
Author(s) -
Stockler Martin
Publication year - 2011
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0167
Subject(s) - medicine , sunitinib , sorafenib , everolimus , renal cell carcinoma , oncology , quality of life (healthcare) , placebo , pathology , alternative medicine , nursing , hepatocellular carcinoma
The results of quality of life analyses from a randomized, placebo‐controlled phase III trial of everolimus for metastatic renal cell carcinoma patients progressing after treatment with sunitinib or sorafenib are reviewed.